Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Inflammatory Bowel Diseases

Free Subscription 16.03.2026 4 Aliment Pharmacol Ther 2 Am J Gastroenterol 2 BMC Gastroenterol 4 Clin Gastroenterol Hepatol 6 Dig Dis Sci 1 Dis Colon Rectum 3 Eur J Gastroenterol Hepatol 3 Gastroenterology 1 Gut 5 Inflamm Bowel Dis 2 J Clin Gastroenterol 6 J Crohns Colitis 1 J Gastroenterol 1 Mediators Inflamm

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. RUEDA GARCIA JL, Suarez Ferrer C, Garcia de la Filia Molina I, Rivas C, et al
   Post-Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU.
   Aliment Pharmacol Ther. 2026 Mar 12. doi: 10.1111/apt.70608.
   PubMed         Abstract available
   
   
2. VAN WEES JC, Little RD, Melton SL
   Letter: Eating Disorders in Inflammatory Bowel Disease-Are We Asking the Right Questions?
   Aliment Pharmacol Ther. 2026 Mar 10. doi: 10.1111/apt.70582.
   PubMed        
   
   
3. FONS AB, Asscher VER, Stuyt RJL, Baven-Pronk AMC, et al
   Frailty Is Associated With All-Cause and Acute Hospitalisations During 18 Months Follow-Up in Older Patients With Inflammatory Bowel Disease.
   Aliment Pharmacol Ther. 2026 Mar 8. doi: 10.1111/apt.70594.
   PubMed         Abstract available
   
   
4. YZET C, Plancke A, Brazier F, Grados L, et al
   Intestinal Ultrasound Transmural Healing Was Associated With Improved Long-Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study.
   Aliment Pharmacol Ther. 2026;63:992-999.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

5. LIE M, Skjernaa SR, Klitgaard KMM, Michno HS, et al
   Phenotypic presentation of pediatric inflammatory bowel disease through 4 decades: The Pediatric NorDIBD cohort.
   Am J Gastroenterol. 2026 Mar 3. doi: 10.14309/ajg.0000000000003986.
   PubMed         Abstract available
   
   
6. CHAMBERS CD, Johnson DL, Luo Y, Xu R, et al
   Birth Outcomes in Women Who Have Taken Vedolizumab in Pregnancy: Results From the Vedolizumab Pregnancy Exposure Registry.
   Am J Gastroenterol. 2026;121:720-732.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

7. ZHANG C, Huang X
   Clinical and biochemical factors associated with moderate-to-severe ulcerative colitis: a retrospective case-control study.
   BMC Gastroenterol. 2026 Mar 12. doi: 10.1186/s12876-026-04712.
   PubMed        
   
   
8. ITO A, Murasugi S, Koroku M, Yonezawa M, et al
   Tacrolimus therapy for ulcerative colitis: a retrospective study of factors associated with inducing and maintaining remission.
   BMC Gastroenterol. 2026 Mar 5. doi: 10.1186/s12876-026-04670.
   PubMed        
   
   

   
   Clin Gastroenterol Hepatol

9. NEVES JC, Leal T, Fernandes S, Sousa DC, et al
   EARLY INTERVENTION PREVENTS DISEASE PROGRESSION IN ULCERATIVE COLITIS - A MULTICENTER RETROSPECTIVE STUDY.
   Clin Gastroenterol Hepatol. 2026 Feb 26:S1542-3565(26)00141.
   PubMed         Abstract available
   
   
10. PANACCIONE R, Panes J, Peyrin-Biroulet L, Colombel JF, et al
    Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.
    Clin Gastroenterol Hepatol. 2026 Feb 26:S1542-3565(26)00145.
    PubMed         Abstract available
    
    
11. CHETWOOD JD, Little RD
    Subcutaneous Infliximab and Assumptions of Response in Ileal Crohn's Disease: Does Route of Administration Matter?
    Clin Gastroenterol Hepatol. 2026 Mar 5:S1542-3565(26)00151.
    PubMed        
    
    
12. SANDS BE, Barnes EL, D'Haens G, Hisamatsu T, et al
    Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn's disease: Results from the VIVID-2 Open-Label Extension Trial.
    Clin Gastroenterol Hepatol. 2026 Mar 5:S1542-3565(26)00155.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

13. OKEGUNNA Y, Sekar M, Adriaans GMC, Cloots MJJ, et al
    Advancing Predictive Modeling of Inflammatory Bowel Disease (IBD) Flares: A Data-Driven Approach Using Lifestyle and Psychosocial Factors from a Remote Monitoring Platform.
    Dig Dis Sci. 2026 Mar 12. doi: 10.1007/s10620-026-09750.
    PubMed         Abstract available
    
    
14. TAN T, Vincent M, Jain U, Deepak P, et al
    Metabolomic Profiling of Fecal Samples Reveals Distinct Signatures Associated with Disease Phenotypes and Locations in Crohn's Disease.
    Dig Dis Sci. 2026 Mar 9. doi: 10.1007/s10620-026-09779.
    PubMed         Abstract available
    
    
15. ELDESOUKI MH, Ibrahim A, Alkasabrah O, Youssef MY, et al
    Severe Influenza-Related Outcomes in Patients with Inflammatory Bowel Disease on Immunosuppressive Therapy: A Propensity-Matched Cohort Analysis.
    Dig Dis Sci. 2026 Mar 6. doi: 10.1007/s10620-026-09773.
    PubMed         Abstract available
    
    
16. LI WAI SUEN CFD, Kaul S, Tan EXZ, Con D, et al
    Monocyte Distribution Width Differentiates Bacterial Enterocolitis from Acute Severe Ulcerative Colitis in the Emergency Department.
    Dig Dis Sci. 2026 Mar 2. doi: 10.1007/s10620-026-09786.
    PubMed         Abstract available
    
    
17. SANO Y, Yagi N, Ito Y, Nakamura N, et al
    Effect of 5-Aminosalicylate Dose Reduction or Withdrawal on Prognosis in Patients with Ulcerative Colitis Receiving Advanced Therapy: A Multicenter Retrospective Cohort Study.
    Dig Dis Sci. 2026 Mar 2. doi: 10.1007/s10620-026-09778.
    PubMed         Abstract available
    
    
18. CHANG A, Oh J, Shin A, Oser M, et al
    Similar Symptoms, Distinct Syndromes: Multi-modal Approach to the Patient with an IBD-IBS Overlap.
    Dig Dis Sci. 2025 Oct 18. doi: 10.1007/s10620-025-09473.
    PubMed         Abstract available
    
    

    
    Dis Colon Rectum

19. YANG Q, Yang J, Yin P, Li X, et al
    Tumor Necrosis Factor Alpha Inhibitors Reduce Staged Surgery Rate and Prevent Postoperative Endoscopic Recurrence in Crohn's Disease Patients.
    Dis Colon Rectum. 2026 Mar 12. doi: 10.1097/DCR.0000000000004194.
    PubMed         Abstract available
    
    

    
    Eur J Gastroenterol Hepatol

20. PRODANOVA D, Janeva A, Drobne D, Novak G, et al
    Applicator preferences for subcutaneous biologics in inflammatory bowel disease: influence on patient satisfaction and willingness to switch treatment.
    Eur J Gastroenterol Hepatol. 2026;38:455-460.
    PubMed         Abstract available
    
    
21. SONG T, Chen Y, Zhang C, Sun Z, et al
    Stricturing phenotype is associated with an increased risk of postoperative surgical recurrence in isolated small bowel Crohn's disease.
    Eur J Gastroenterol Hepatol. 2026;38:442-449.
    PubMed         Abstract available
    
    
22. COELHO RODRIGUES I, Fernandes SR, Saraiva S, Goncalves AR, et al
    Fecal calprotectin-guided treatment escalation strategy enhances disease clearance in ulcerative colitis.
    Eur J Gastroenterol Hepatol. 2026;38:431-436.
    PubMed         Abstract available
    
    

    
    Gastroenterology

23. KOTLARZ D
    Rewiring wound healing in Crohn's Disease - Fibroblast niches as the architects of fistula formation.
    Gastroenterology. 2026 Mar 10:S0016-5085(26)00206.
    PubMed        
    
    
24. BRAUN T, Levhar N, Efroni G, Hadar R, et al
    Perturbations of Diet and Gut Signatures Persist During Remission in Crohn's Disease Despite Effective Immune Suppression.
    Gastroenterology. 2026 Mar 9:S0016-5085(25)06618.
    PubMed         Abstract available
    
    
25. NARULA N, Wong ECL, Rangarajan S, Miller V, et al
    Association Between Ultraprocessed Food Intake and Inflammatory Bowel Disease Risk: A Propensity-Matched Analysis With Monte Carlo Simulation From the Prospective Urban Rural Epidemiology Study.
    Gastroenterology. 2026 Mar 9:S0016-5085(25)06617.
    PubMed        
    
    

    
    Gut

26. NEURATH MF, Vieth M
    Different levels of healing in inflammatory bowel diseases: mucosal, histological, transmural, barrier and complete healing.
    Gut. 2023;72:2164-2183.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

27. SANDS BE, Clemow DB, D'Haens G, Irving PM, et al
    Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.
    Inflamm Bowel Dis. 2026 Mar 2:izag007. doi: 10.1093.
    PubMed         Abstract available
    
    
28. GEICULESCU I, Niklinska-Schirtz BJ, Munasinghe S, Rajendra C, et al
    Unique challenges faced by tweens and teens with inflammatory bowel disease: a global perspective.
    Inflamm Bowel Dis. 2026 Feb 28:izag010. doi: 10.1093.
    PubMed         Abstract available
    
    
29. TSILIMPOTIS D, Kyriakou G, Biedermann L, Vavricka S, et al
    Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.
    Inflamm Bowel Dis. 2026;32:542-561.
    PubMed         Abstract available
    
    
30. MUNERA-RODRIGUEZ AM, Leiva-Castro C, Reina-Perez I, Benitez-Marquez JM, et al
    The Role of Autophagy in Inflammatory Diseases: Challenges and Therapeutic Potential.
    Inflamm Bowel Dis. 2026;32:562-571.
    PubMed         Abstract available
    
    
31. ROBBERTZ A, Hommel K, Keefer L, Reed B, et al
    Model psychosocial care for youth with inflammatory bowel disease.
    Inflamm Bowel Dis. 2026 Feb 28:izag005. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Clin Gastroenterol

32. KHALIL C, Mehra M, Yang Y, Choi SY, et al
    Development and Validation of Crohn's Perianal Fistula Educational Videos and Website for Increasing Patient Knowledge and Engagement.
    J Clin Gastroenterol. 2026;60:363-371.
    PubMed         Abstract available
    
    
33. TARIQ R, Sterling RK, Afzali A, Sanyal AJ, et al
    From Gut to Metabolism: Exploring the Intersection of Inflammatory Bowel Disease and Systemic Metabolic Dysfunction.
    J Clin Gastroenterol. 2026 Mar 11. doi: 10.1097/MCG.0000000000002359.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

34. WANG Y, Tian G
    Prior anti-tumor necrosis factor exposure and colectomy risk in acute severe ulcerative colitis: time-to-event and target-trial considerations in MOREUS (GETECCU).
    J Crohns Colitis. 2026;20:jjag020.
    PubMed        
    
    
35. SINGH A, Bhardwaj A, Jena A, Midha V, et al
    Patient knowledge and awareness on inflammatory bowel disease as it evolves as a global disease: a scoping review.
    J Crohns Colitis. 2026;20:jjag019.
    PubMed         Abstract available
    
    
36. DIGNASS A, Narula N, Pratap K, Danese S, et al
    IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease.
    J Crohns Colitis. 2026;20:jjag007.
    PubMed         Abstract available
    
    
37. CHKOLNAIA Z, Peyrin-Biroulet L, Uzzan M
    A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases.
    J Crohns Colitis. 2026;20:jjag009.
    PubMed         Abstract available
    
    
38. JATKOWSKA A, White B, Nichols B, Svolos V, et al
    Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance.
    J Crohns Colitis. 2023;17:1426-1435.
    PubMed         Abstract available
    
    
39. AMIOT A, Chaibi S, Bouhnik Y, Serrero M, et al
    Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID.
    J Crohns Colitis. 2023;17:1418-1425.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

40. TSURUOKA N, Takedomi H, Sakata Y, Fujioka S, et al
    Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team.
    J Gastroenterol. 2026 Mar 10. doi: 10.1007/s00535-026-02383.
    PubMed         Abstract available
    
    

    
    Mediators Inflamm

41. LI S, Yuan G, Chen C, Lu J, et al
    Wenyang Decoction Ameliorates DSS-Induced Ulcerative Colitis by Regulating Macrophage Polarization and the PI3K/AKT/mTOR/HIF-1alpha Signaling Pathway.
    Mediators Inflamm. 2026;2026:7737168.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum